Skip to main content
Terug
RPHCF logo

Rohto Pharmaceutical Co.,Ltd.

Datakwaliteit: 100%
RPHCF
OTC Consumer Defensive Household & Personal Products
€ 15,20
€ 0,00 (0,00%)
Marktkapitalisatie: 3,43B
Dagbereik
€ 15,20 € 15,20
52-Weeksbereik
€ 14,34 € 20,09
Volume
150
50D / 200D Gem.
€ 15,96 / € 15,28
Vorige Slotkoers
€ 15,20

Koershistorie

Financiële Trends

Sectorvergelijking

vs Consumer Defensive sector mediaan (329 peers)

Metriek Aandeel Sector Mediaan
P/E 0,1 10,4
P/B 0,0 1,2
ROE % 12,3 12,6
Net Margin % 10,1 5,3
Rev Growth 5Y % 14,3 5,5
D/E 0,2 0,6

Belangrijkste Punten

Revenue grew 14,26% annually over 5 years — strong growth
ROE of 12,25% — decent returns on equity
Debt/Equity of 0,19 — conservative balance sheet
Generating 26,36B in free cash flow
P/E of 0,11 — trading at a low valuation
Cash machine — converts 85,00% of earnings into free cash flow

Groei

Revenue Growth (5Y)
14,26%
Revenue (1Y)13,95%
Earnings (1Y)0,23%
FCF Growth (3Y)1190,78%

Kwaliteit

Return on Equity
12,25%
ROIC9,41%
Net Margin10,05%
Op. Margin12,62%

Veiligheid

Debt / Equity
0,19
Current Ratio2,30
Interest Coverage41,03

Waardering

P/E Ratio
0,11
P/B Ratio0,01
EV/EBITDA-0,60
Dividend Yield0,01%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 13,95% Revenue Growth (3Y) 13,72%
Earnings Growth (1Y) 0,23% Earnings Growth (3Y) 8,42%
Revenue Growth (5Y) 14,26% Earnings Growth (5Y) 16,65%
Profitability
Revenue (TTM) 308,63B Net Income (TTM) 31,01B
ROE 12,25% ROA 7,35%
Gross Margin 56,68% Operating Margin 12,62%
Net Margin 10,05% Free Cash Flow (TTM) 26,36B
ROIC 9,41% FCF Growth (3Y) 1190,78%
Safety
Debt / Equity 0,19 Current Ratio 2,30
Interest Coverage 41,03 Dividend Yield 0,01%
Valuation
P/E Ratio 0,11 P/B Ratio 0,01
P/S Ratio 0,01 PEG Ratio 58,85
EV/EBITDA -0,60 Dividend Yield 0,01%
Market Cap 3,43B Enterprise Value -23,50B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 308,63B 270,84B 238,66B 199,65B 181,05B
Net Income 31,01B 30,94B 26,38B 21,13B 16,74B
EPS (Diluted) 135,44 135,21 115,29 92,34 73,18
Gross Profit 174,94B 157,29B 1,02B 937,32M 949,85M
Operating Income 38,94B 40,05B 33,96B 29,02B 22,99B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 421,88B 346,18B 2,33B 2,26B 2,05B
Total Liabilities 150,44B 99,14B 712,02M 746,57M 629,28M
Shareholders' Equity 260,09B 246,32B 1,58B 1,47B 1,41B
Total Debt 50,22B 10,49B 102,46M 21,38B 8,10B
Cash & Equivalents 77,16B 89,21B 584,78M 582,48M 472,90M
Current Assets 217,88B 214,76B 1,43B 1,35B 1,20B
Current Liabilities 94,61B 87,09B 603,38M 587,27M 511,05M

Strategiescores

This stock passed the criteria for 4 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Cash Flow Compounder
#406 of 1024
50
Custom Deep Value Investing (Seth Klarman)
#157 of 820
59
Growth Price/Sales Ratio Focus (Ken Fisher)
#491 of 616
16
Value Defensive Investing (Benjamin Graham)
#377 of 708
27

Recente Activiteit

Ingestapt Cash Flow Compounder
Mar 24, 2026
Ingestapt Deep Value Investing (Seth Klarman)
Mar 24, 2026
Ingestapt Price/Sales Ratio Focus (Ken Fisher)
Mar 24, 2026
Ingestapt Defensive Investing (Benjamin Graham)
Mar 24, 2026